Muscle biopsy findings in inflammatory myopathies

Rheumatic Disease Clinics of North America

Volumn 28, Issue 4, 2002, Pages 779-798

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOMYOSITIS; ELECTRON MICROSCOPY; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; INCLUSION BODY MYOSITIS; INFLAMMATORY DISEASE; INFLAMMATORY INFILTRATE; MUSCLE BIOPSY; MUSCLE DISEASE; MYOPATHY; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW;

BIOPSY; CRYOPRESERVATION; CRYOULTRAMICROTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; MYOSITIS; SPECIMEN HANDLING;

EID: 0036866049     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(02)00030-3     Document Type: Review

References (47)

1. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991;325:1487-98.
2. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. In: Braunwald E, Fauci AS, Kasper DL, et al, editors. Harrison's Principles of Internal Medicine. 15th Edition. New York: McGraw-Hill; 2001. p. 2524-9.
3. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995;37(Suppl 1):S74-86.
4. Dalakas MC. Inflammatory myopathies: Recent advances in pathogenesis and therapy. Adv Neurol 2001;88:253-71.
5. Engel AG, Hohfeld R, Banker BQ. The polymyositis and dermatomyositis syndromes. In: Engel AG, Franzini-Armstrong C, editors. Myology. 2nd Edition. New York: McGraw-Hill Book Co.; 1994. p. 1335-83.
6. Carpenter S, Karpati G. Pathology of Skeletal Muscle. New York: Oxford Univ Press; 2001.
7. Dalakas MC, Karpati G. The inflammatory myopathies. In: Disorders of Voluntary Muscle. Karpati G, Hilton-Jones D, Griggs RC, editors. 7th edition. Cambridge (UK): Cambridge University Press; 2001. p. 636-59.
8. Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol Today 1994;15:269-74.
9. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986;314:329-34.
10. Sekul EA, Dalakas MC. Inclusion body myositis: New concepts. Semin Neurol 1993;13:256-63.
11. Askanas V, Engel WK. Sporadic inclusion body myositis and hereditary inclusion-body myopathies. Arch Neurol 1988;55:915-20.
12. Askanas V, Engel WK, Alvarez RB. Idiopathic inflammatory myopathies: Inclusion-body myositis, polymyositis, and dermatomyositis. Curr Opin Neurol Neurosurg 1994;7:448-56.
13. Semino-Mora C, Dalakas MC. Rimmed vacuoles with β-amyloid and ubiquinated filamentous deposits in the muscles of patients with long-standing denervation (post-poliomyelitis muscular atrophy): Similarities with inclusion body myositis. Human Pathol 1998;29:1128-33.
14. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988;23:64-72.
15. Nyberg P, Wikman AL, Nennesmo I, et al. Increased expression of interleukin 1α and MHC Class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 2000;27:940-8.
16. Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies. Duchenne's dystrophy and non-weak controls. J Neuroimmunol 1995;63:9-16.
17. Tews DS, Goebel HH. Cytokine expression profiles in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996;55:342-7.
18. Illa I, Gallardo E, Gimeno R, et al. Signal transducer and activator of transcription I in human muscle: Implications in inflammatory myopathies. Am J Pathol 1997;151:81-8.
19. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: A quantitative study. Ann Neurol 1990;27:343-56.
20. Banker BQ. Dermatomyositis of childhood. Ultrastructural alterations of muscle and intramuscular blood vessels. J Neurop Exp Neurol 1975;35:46-75.
21. Dalakas MC, Pezeshkpour GH. Neuromuscular diseases associated with human immunodeficiency virus infection. Ann Neurol 1988;23(S):38-48.
22. Stein DP, Dalakas MC. Intercellular adhesion molecule-I expression is upregulated in patients with dermatomyositis (DM). Ann Neurol 1993;34:268 [abstract].
23. Sivakumar K, Dalakas MC. Inclusion body myositis and myopathies. Curr Opin Neurol 1997;10:413-20.
24. Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Gen 2001;29:83-7.
25. Sivakumar K, Dalakas MC. The spectrum of familial inclusion body myopathies in 13 families and description of a quadriceps sparing phenotype in non-Iranian Jews. Neurology 1996;47:977-84.
26. Hohlfeld R, Goebels N, Engel AG. Cellular mechanisms in inflammatory myopathies. In: Mastaglia FL, editor. Bailliere's Clinical Neurology. London: W.B. Saunders Co.; 1993. p. 617-36.
27. Dalakas MC, Illa I. Common variable immunodeficiency and inclusion body myositis: A distinct myopathy mediated by natural killer cells. Ann Neurol 1995;37:806-10.
28. Askanas V, Serdaroglu P, Engel WK, et al. Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light-microscopic distinction from polymyositis. Neurology 1992;42:460-1.
29. Santorelli FM, Sciacco M, Tanji K, et al. Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: A study of 56 patients. Ann Neurol 1996;39:789-95.
30. Hohlfeld R, Engel AG. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 1991;29:498-507.
31. Goebel N, Michaelis D, Engelhardt M, et al. Differential expression of perforin in muscleinfiltrating T cell in polymyositis and dermatomyositis. J Clin Invest 1996;97:2905.
32. Behrens L, Bender A, Johnson MA, et al. Cytotoxic mechanisms in inflammatory myopathies: Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 1997;120:929.
33. Schneider C, Gold R, Dalakas MC, et al. MHC class I mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: Studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropath Exp Neurol 1996;55:1205-9.
34. Mantegazza R, Andreetta F, Bernasconi P, et al. Analysis of T cell receptor repertoire of muscle infiltrating T lymphocytes in polymyositis: Restricted V a/b rearrangements may indicate antigendriven selection. J Clin Invest 1993;91:2880-6.
35. O'Hanlon TP, Dalakas MC, Plotz PH, et al. Predominant I T cell receptor variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol 1994;152:2569-76.
36. Bender A, Ernst N, Iglesias A, et al. T cell receptor repertoire in polymyositis: Clonal expansion of autoaggressive CD8 T Cells. J Exp Med 1995;181:1863-8.
37. Fyhr IM, Moslemi AR, Mosavi AA, et al. Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis. J Neuroimmunol 1997;79:185-9.
38. Amemiya K, Granger RP, Dalakas MC. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time: Studies in repeated muscle biopsies. Brain 2000;123:2030-9.
39. Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNA in inflammatory myopathies. Am J Pathol 1999;155:453-60.
40. Behrens L, Kerschensteiner M, Misgeld T, et al. Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 1998;161:5943-51.
41. Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 2000;54:65-71.
42. De Bleecker JL, Meire VI, Declercq W, et al. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromusc Disord 1999;9:239.
43. Dalakas MC. The molecular and cellular pathology of inflammatory muscle diseases. Curr Opin Pharmacol 2001;1:300-6.
44. Dalakas MC, Pezeshkpour GH, Gravell M, et al. Polymyositis in patients with AIDS. JAMA 1986;256:2381-3.
45. Leon-Monzon M, Illa I, Dalakas MC. Polymyositis in patients infected with HTLV-I: The role of the virus in the cause of the disease. Ann Neurol 1994;36:643-9.
46. Illa I, Nath A, Dalakas MC. Immunocytochemical and virological characteristics of HIV-associated inflammatory myopathies: Similarities with seronegative polymyositis. Ann Neurolo 1991;29:474-81.
47. Cupler EJ, Leon-Monzon M, Miller J, et al. Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain 1996;119:1887-93.